PubMed Health⌕ Search

Biomedical subjects

L V Moroz

Publications and source records attributed to L V Moroz.

At least 19 recordsLinked to original sources
PubMed1995

[Phenomenon of tumor growth stability in the host's body. New approach to growth and treatment of tumors].

The impact of surgical treatment of Ehrlich's carcinoma on animals' survival was studied. Tumour removal on posttransplantation day 30 was shown to cause no increases in the longevity of the animals operated on as compared with those non-operated on (mean longevity was 59.9 and 62.2 days, respectively). The death causes of the animals operated on were metastases and relapses. On day 7 after transplantation, cyclophosphanum therapy of Ehrlich's carcinoma failed to prolong the animals' life. While 24 hours after tumour transplantation the longevity increased from 61.8 to 93.4 days. No therapeutical effects were shown to be associated with the influence of humoral factors of the host body on tumor growth. It was shown that the lack of these humoral factors resulted in interrupting tumor growth.

Animals↗
PubMed1992

[The effect of ascitic fluid globulins on the growth of leukemia P388/DOX and Ehrlich's carcinoma in mice].

The study was performed to investigate the effect of ascitic fluid globulins of tumor on tumor growth and life span of mice. The globulins are shown to shorten the life span of Ehrlich tumor mice from 86.8 to 61.8 days, to increase 3-5-fold the growth rate of Ehrlich carcinoma and P388/DOX tumor. It was found that globulins of ascitic fluids and serum globulins of tumor have equal effects of tumor growth. It is proposed to use globulins of ascitic fluid to study the globulin role in tumor growth.

Animals↗
PubMed1992

[The characteristics of Ehrlich carcinoma recurrence and metastasis].

It was shown that surgical removal of Ehrlich carcinoma growing i. m. in male mice F1 (CBA C57Bl/6) does not entail longer survival in comparison with intact tumor-bearing mice (59.4 and 62.2 days, respectively). Postoperative relapses appear in 40-60% of the animals, metastases in 100% of animals. Metastases were not observed in intact tumor bearing mice. The second-challenge tumor was not observed in operated mice despite metastatic growth and recurrences of the same tumor. We suggest that metastatic growth depends on the tumor cell features and that this process is controlled by host organism.

Animals↗
PubMed1992

[Mouse serum inhibition of cytotoxicity of goat antibodies against mouse thymocytes].

It is shown that the serum of Balb/c, C57Bl/6 and F1(C57Bl/6 x CBA) mice inhibits cytotoxicity of goat antithymocyte antibodies. The addition of the serum into the incubation medium increases the proportion of alive cells from -5% up to 95%. Cytotoxicity was also inhibited by the globulin fraction of the mice serum. It is suggested that normal mice serum contains factors which block cytotoxicity of antibodies against antigen host determinants.

Animals↗
PubMed1992

[The effect of ascitic fluid on the growth of Ehrlich tumor and Lewis carcinoma].

In the study of the effect of ascitic fluid and dialysate of Ehrlich ascites tumor cells (m.m. less than 15 kDa) on the growth of Ehrlich and Lewis carcinoma it was found that the ascitic fluid significantly decreased the size of Ehrlich tumor (by more than 50% on day 9-25 after the tumor cell inoculation). It also reduced Lewis carcinoma tumor volume by more than 30% during 3 weeks after the tumor cells inoculation. Dialysate of Ehrlich tumor cells significantly inhibited the growth of Ehrlich tumor too. It is suggested that this test-system simulates inhibition of a small tumor by a big tumor in vivo.

Animals↗
PubMed1992

[The modelling of the growth of Ehrlich carcinoma and teratoma T-36 with ascitic fluid and tumor-cell dialysate].

The study of the effect of ascitic fluid and dialysate of Ehrlich ascites tumor cells (M.m. less than 15 kDa) on the growth of Ehrlich carcinoma and teratoma T-36 has shown that both the ascitic fluid and dialysate can protect tumor cells in vivo. The number of animals with tumors increased from 0% in control animals to 60 and 20%, respectively, in experimental ones after transplantation i.m. of 20 x 10(3) Ehrlich tumor cells into mice. Compared to control, ascitic fluid and dialysate of Ehrlich ascites tumor cells increased the rate of tumor growth to 195 and 153%, respectively. It is suggested that this test-system simulates the effect of tumor humoral factors in vivo.

Animals↗
PubMed1991

[The expression of P-glycoprotein in leukemia P388 cells with induced doxorubicin resistance].

beta-D-galactose-containing glycoproteins were prepared from cells P-388 leukemia and from P-388 leukemia cells with induced resistance to doxorubicin. It was shown by HPLC method that plasma membranes from resistant cells contain 4-4.5% P-glycoproteins and plasma membranes from sensitive cells contain P-glycoproteins about 10 times lower.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMed1991

[Changes in glutathione-S-transferase activity during induction of resistance of leukemia P 388 and Ehrlich ascitic tumor cells to doxorubicin].

We have studied by uridine short term test the level of resistance of murine leukemia cell lines P 388/Dx and ELD/Dx carcinoma cells with induced resistance to doxorubicin, P 388/Fp + Dx cells with induced resistance to combination of finoptOFF++ and doxorubicin in vivo. It was shown that the level of resistance was 6 fold for P 388/Dx cells, 4.5 fold for ELD/Dx cells and 2 fold for P 388/Fp + Dx cells. It was shown that the P 388/Dx cells and P 388/Fr + Dx cells had a 3.5 and 4.4 fold increase level of glutathione-S-transferase activity than P 388 cells. No increase in the activity of glutathione-S-transferase was detected in ELD/Dx cells. We conclude that increase of cellular glutathione-S-transferase activity is not associated with the development of resistance to doxorubicin.

Animals↗
PubMed1991

[Effect of Triton X-100 on accumulation and therapeutic effect of doxorubicin in mice with leukemia P-388 with induced resistance to cytostatic agents].

Using P 388 and P 388/Dx tumour-bearing mice BDF1 it has been studied effect Tritton X-100 on accumulation and therapeutic action of doxorubicin (Dx). It has been shown that LD50 of Tritton X-100 is 153.6 mg/kg and MTD is 80 mg/kg body weight of animals. It has been shown that Tritton X-100 in dose 40 mg/kg body weight increases initial level of Dx in P 388/Dx cells to 215% and doesn't change accumulation of Dx in P 388 cells. It has been shown that Tritton X-100 doesn't influence the therapeutic effect of Dx in P 388 and P 388/Dx tumour-bearing mice.

Animals↗